Jpmorgan Chase & CO Ocular Therapeutix, Inc Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 85,373 shares of OCUL stock, worth $876,780. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85,373
Previous 69,226
23.33%
Holding current value
$876,780
Previous $629,000
7.31%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding OCUL
# of Institutions
157Shares Held
139MCall Options Held
86.4KPut Options Held
263K-
Summer Road LLC West Palm Beach, FL14.9MShares$153 Million98.56% of portfolio
-
Vr Adviser, LLC New York, NY12.8MShares$131 Million9.58% of portfolio
-
Deep Track Capital, LP Greenwich, CT12.7MShares$131 Million2.86% of portfolio
-
Black Rock Inc. New York, NY11.5MShares$118 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.61MShares$88.4 Million0.0% of portfolio
About OCULAR THERAPEUTIX, INC
- Ticker OCUL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,966,896
- Market Cap $790M
- Description
- Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...